CClinicalTrials.gg
CompletedNCT04849403Updated Apr 19, 2021

TROCAR SITE HERNIA AFTER LSG

An interventional study of CTSP in Obesity, Morbid and Hernia Incisional, sponsored by Fatih Sultan Mehmet Training and Research Hospital. Completed at 1 site in Turkey. Open to participants aged 16 Years to 90 Years. Per ClinicalTrials.gov, last updated 2021-04-19.

Sponsored by Fatih Sultan Mehmet Training and Research Hospital · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Registered 6 years 3 months after the study started (first participant enrolled Jan 2015, registered Apr 2021).
Phase
Not applicable
Study type
Interventional
Enrollment
61
Allocation
Not applicable
Ages
16 Years to 90 Years
Sex
All
01

Study summary

Today, laparoscopic sleeve gastrectomy (LSG) has become the most frequently performed bariatric surgical method. One of the complications seen after LSG is trocar site hernia (TSH). There is no clear information about the rate of TSH detected radiologically after LSG. Thick abdominal wall and failure to adequately expose the facial defect related to this, mobility limitations due to excessive subcutaneous fatty tissue are the reasons accused for increased incidence of TSH.

Demographic characteristics and postoperative weight loss of patients who underwent LSG procedure in our clinic between January 2015 and June 2017 and whose facial defects in the trocar region were repaired with the Carter-Thomason Suture Passer (CTSP) were evaluated. TSH evaluation was made both by physical examination and superficial USG by a general surgeon who had radiological training on concurrent superficial abdominal ultrasonography (USG). Detected TSHs were divided into two groups as symptomatic and asymptomatic.

Read the detailed description

This study included 61 patients who applied to the obesity follow-up outpatient clinic for any complaints or routine control over a 3-month period or who were called by telephone for control and who underwent laparoscopic sleeve gastrectomy for morbid obesity between January 2015- June 2017. Patients with symptoms associated with trocar site hernia were also included in the study, while patients with multiple bariatric surgical procedures or abdominal operations were excluded. Physical examinations to detect hernias were performed both in standing and supine positions for all patients and also during increased abdominal pressure by the Valsalva maneuver. All abdominal incision sites were examined. On physical examination, a hernia was defined as a bulging during the Valsalva maneuver and palpation of the fascial defect. USG was performed (Figure I,II) by a clinician who had previously received superficial USG evaluation training for trocar site hernia with a GE pro 500, 3 MHz and abdominal incision sites were investigated for the presence of hernias.

The trocar entry localizations of the patients were all the same and are as follows: one 15-mm camera trocar (supraumbilical) , one 10-mm working trocar (left upper quadrant), two 5-mm working trocars (right and left upper quadrant) and one 5-mm liver retractor. Trocar entry localizations are shown in Figure III. During fascia closure procedure, No. 0 absorbable suture (PolyglactinYü-ce Vicryl Ⓡ, Tekirdag, Turkey ) was used with the CTSP (Figure IV). The collected data were recorded in a pre-established database with age, gender, Diabetes Mellitus (DM), postoperative follow-up period, BMI at the time of operation and BMI during superficial USG.

This study was approved by the Ethics Committee of University of Health Sciences Istanbul Fatih Sultan Mehmet Training and Research Hospital (12.09.2019 / 80).

02

Conditions studied

  • Obesity, Morbid
  • Hernia Incisional

Keywords

  • Laparoscopic Sleeve Gastrectomy
  • Morbid obesity
  • Trocar site hernia
  • Carter Thomasson Suture Passer
03

In context

Obesity, Morbid

922 studies on the registry are indexed under Obesity, Morbid; 172 are open to participants now.

This study's enrollment of 61 is close to the median of 60 across 590 interventional studies indexed under Obesity, Morbid.

Browse Obesity, Morbid studies →

Lead sponsor

Fatih Sultan Mehmet Training and Research Hospital is the lead sponsor of 118 studies on the registry; 34 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • The patients above 18 years old.
  • The patient who went Laparoscopic Sleeve Gastrectomy (LSG) procedure for morbid obesity.

Exclusion criteria

Exclusion Criteria:

  • The patients who needed to have additional surgery after the LSG in their follow up.
  • The patients who could not reached and did not attend to the Ultrasound examination.
  • The patient who did not approve the participate to the study.
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
61 participants (actual)

Study arms

  • Other
    The group USG was applied

    USG was applied to the patients who underwent Laparoscopic sleeve gastrectomy for research trocar site hernia after 2-4 years from the surgery. Carter Thomasson suture passer was used to close fascial defect in all patients.

    Procedure: CTSP

Interventions

  • ProcedureCTSP

    In all patients Carter Thomasson Suture Passer (CTSP) were used for closing fascial defect peroperatively

06

What researchers measure

Primary outcomes

  1. incidence of incisional hernia

    Superficial abdominal Ultrasound for the incisional hernia to trocar sites.

    Time frame: 2-4 years

07

Study locations

1 site
  • Anıl Ergin
    Istanbul, 34734, Turkey
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 19, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04849403
Lead sponsor
Fatih Sultan Mehmet Training and Research Hospital
Responsible party
ANIL ERGIN (MD. Anil Ergin, Fatih Sultan Mehmet Training and Research Hospital) — Principal investigator
First posted
Apr 19, 2021
Start date
Jan 1, 2015
Primary completion
Jun 1, 2017
Completion
Jun 1, 2018
Last update
Apr 19, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion